Agilent Technologies, Inc.
https://www.agilent.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Agilent Technologies, Inc.
Keeping Track: US FDA Oncology Approvals For Ferring’s Gene Therapy Adstiladrin And Mirati’s Targeted Therapy Krazati
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price
Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.
Earlier-Stage Approvals For Tecentriq, Keytruda, Verzenio Underscore Broader Oncology Trends
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Swedish Biotech Developing Stem Cell Therapies From Amniotic Fluid
Swedish biotech Amniotics is developing a broad pipeline of unique stem cell therapeutics based on technology that is broadly applicable to major disease markets which should eventually draw the attention of big pharma players, its CEO tells Scrip.
Company Information
- Industry
- Contract Research Organization-CRO
- In Vitro Diagnostics
- Laboratory Testing Services
- Research, Analytical Equipment & Supplies
- Services
-
Pharmaceuticals
- Chiral Chemistry
-
Medical Devices
- Diagnostic Equipment & Supplies
-
Biotechnology
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- ACEA Biosciences
- Advanced Analytical Technologies
- Avida Biomed, Inc.
- BioTek
- Cartagenia
- Dako
- J&W Scientific Inc.
- Lasergen, Inc.
- Luxcel Biosciences
- Multiplicom
- Resolution Bioscience, Inc.
- Seahorse Bioscience
- Silicon Genetics
- Ultra Scientific
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice